J Gynecol Oncol.  2014 Apr;25(2):105-110. 10.3802/jgo.2014.25.2.105.

Survival analysis of endometrial cancer patients with cervical stromal involvement

Affiliations
  • 1Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah School of Medicine, Salt Lake City, UT, USA. David.Gaffney@hci.utah.edu
  • 2Department of Radiation Oncology, Intermountain Medical Center, Murray, UT, USA.
  • 3Department of Gynecological Oncology, Huntsman Cancer Hospital, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • 4Department of Gynecological Oncology, Intermountain Medical Center, Murray, UT, USA.

Abstract


OBJECTIVE
Stage II endometrial cancer is relatively uncommon. There is no consensus for appropriate adjuvant therapy in endometrial cancer patients with cervical stromal involvement (International Federation of Gynecology and Obstetrics [FIGO] stage II). This study investigates how adjuvant treatments and tumor characteristics influence overall survival (OS) and disease-free survival (DFS) in stage II patients in order to establish better treatment guidelines.
METHODS
This multi-institution, Institutional Review Board approved, study is a retrospective review of 40 endometrial cancer patients with cervical stromal involvement treated from 1993 to 2009. Kaplan-Meier estimates were used to evaluate OS and DFS.
RESULTS
OS was 85% at three years and 67% at five years. There were no significant differences in age, histology, depth of invasion, comorbid conditions, surgical staging or recurrence between patients who received radiation therapy (RT) and those who did not. However, patients with FIGO grade 1 cancers were less likely to receive RT (p=0.007). Patients treated with RT had a similar 5 year OS (n=33, 69%) to those treated with surgery only (n=7, 60%, p=0.746). There were no OS differences when evaluating by grade, histology, or depth of invasion between patients who did and did not receive RT. Four patients recurred: three were locoregional failures only, and one failed locally and distant.
CONCLUSION
Patients receiving RT had higher grade tumors. Despite this, OS was comparable between the RT and the no RT cohorts. Local failure was the predominant pattern of failure. Endometrial cancer patients with cervical stromal involvement likely receive better locoregional control with the addition of adjuvant RT and we continue to advocate for RT in most cases.

Keyword

Adjuvant radiation therapy; Cervical involvement; Endometrial cancer; Survival outcome

MeSH Terms

Cohort Studies
Consensus
Disease-Free Survival
Endometrial Neoplasms*
Ethics Committees, Research
Female
Gynecology
Humans
Obstetrics
Recurrence
Retrospective Studies
Survival Analysis*

Figure

  • Fig. 1 Stage II endometrial cancer overall survival for all subjects.


Cited by  1 articles

Treatment outcomes of patients with stage II pure endometrioid-type endometrial cancer: a Taiwanese Gynecologic Oncology Group (TGOG-2006) retrospective cohort study
Hung-Chun Fu, Jen-Ruei Chen, Min-Yu Chen, Keng-Fu Hsu, Wen-Fang Cheng, An-Jen Chiang, Yu-Min Ke, Yu-Chieh Chen, Yin-Yi Chang, Chia-Yen Huang, Chieh-Yi Kang, Yuan-Yee Kan, Sheng-Mou Hsiao, Ming-Shyen Yen
J Gynecol Oncol. 2018;29(5):.    doi: 10.3802/jgo.2018.29.e76.


Reference

1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER cancer statistics review, 1975-2007: based on November 2009 SEER data submission. Bethesda, MD: National Cancer Institute;2010.
2. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980; 56:419–427.
3. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92:744–751.
4. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial: PORTEC Study Group. Post perative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000; 355:1404–1411.
5. Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Burke WM, Sun X, et al. Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' staging system for uterine corpus cancer. Obstet Gynecol. 2010; 116:1141–1149.
6. Lee MH, Aquino-Parsons C, Hoskins PJ, Lim P, Kwon JS. Preoperative radiotherapy for inoperable stage II endometrial cancer: insights into improving treatment and outcomes. J Obstet Gynaecol Can. 2013; 35:635–639.
7. Sartori E, Gadducci A, Landoni F, Lissoni A, Maggino T, Zola P, et al. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer. 2001; 11:430–437.
8. Pitson G, Colgan T, Levin W, Lockwood G, Manchul L, Milosevic M, et al. Stage II endometrial carcinoma: prognostic factors and risk classification in 170 patients. Int J Radiat Oncol Biol Phys. 2002; 53:862–867.
9. Boente MP, Yordan EL Jr, McIntosh DG, Grendys EC Jr, Orandi YA, Davies S, et al. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol. 1993; 51:316–322.
10. Onsrud M, Aalders J, Abeler V, Taylor P. Endometrial carcinoma with cervical involvement (stage II): prognostic factors and value of combined radiological-surgical treatment. Gynecol Oncol. 1982; 13:76–86.
11. Wallin TE, Malkasian GD Jr, Gaffey TA, O'Brien PC, Fountain KS. Stage II cancer of the endometrium: a pathologic and clinical study. Gynecol Oncol. 1984; 18:1–17.
12. Larson DM, Copeland LJ, Gallager HS, Wharton JT, Gershenson DM, Edwards CL, et al. Prognostic factors in stage II endometrial carcinoma. Cancer. 1987; 60:1358–1361.
13. Lanciano RM, Curran WJ Jr, Greven KM, Fanning J, Stafford P, Randall ME, et al. Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium. Gynecol Oncol. 1990; 39:368–373.
14. ASTEC/EN.5 Study Group. Blake P, Swart AM, Orton J, Kitchener H, Whelan T, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009; 373:137–146.
15. ASTEC study group. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373:125–136.
Full Text Links
  • JGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr